ArticleESMO open2024

Corrigendum to "A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone": [ESMO Open 8 (2023) 102033].

J Pearson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.